Healthcare Industry News: Becton, Dickinson
News Release - February 13, 2012
BD Acquires KIESTRA Lab Automation BVProvides Automation Platform to Offer Integrated Microbiology Lab Solutions
FRANKLIN LAKES, N.J., Feb. 13, 2012 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired KIESTRA Lab Automation BV, a Netherlands-based company that designs, develops, manufactures, markets and sells innovative lab automation solutions for the microbiology lab. The financial terms of the acquisition were not disclosed. The transaction is expected to be slightly dilutive; however, BD reaffirms its previous guidance that reported diluted earnings per share from continuing operations for fiscal year 2012 are expected to be in the range of $5.60 to $5.70.
For further information, read more on BD's website.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.